ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,099.96
      1.02%
      US Tech 100
      17,244.00
      1.57%
      Dow Jones
      38,239.66
      0.40%
      Brent Oil
      88.165
      0.00%
      Bitcoin
      62,896.22
      -1.32%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Biogen Inc (BIIB) Quote

      BIIB Biogen Inc

      208.50
      6.04 (2.98%)
      Apr 26 2024 - Closed
      Delayed by 15 minutes

      Period:

      Draw Mode:

      Volume 1,894,099
      Bid Price 208.50
      Ask Price 208.59
      News -
      Day High 210.83

      Low
      189.44

      52 Week Range

      High
      319.76

      Day Low 199.10
      Company Name Stock Ticker Symbol Market Type
      Biogen Inc BIIB NASDAQ Common Stock
        Price Change Change Percent Stock Price Last Traded
      Upgrade Icon
      6.04 2.98% 208.50 19:47:07
      Open Price Low Price High Price Close Price Prev Close
      201.22 199.10 210.83 208.90 202.46
      Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
      40,928 1,894,099 $ 207.20 $ 392,462,408 - 189.44 - 319.76
      Last Trade Time Type Quantity Stock Price Currency
      19:51:57 2 $ 208.50 USD

      Biogen (BIIB) Options Flow Summary

      Overall Flow

      Bearish

      Net Premium

      -43M

      Calls / Puts

      28.79%

      Buys / Sells

      95.24%

      OTM / ITM

      23.19%

      Sweeps Ratio

      0.00%

      View BIIB Options Flow >>

      Biogen Inc Financials
      Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
      30.37B 145.36M - 9.84B 1.16B 7.99 26.15
      Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
      - - - -

      more financials information »

      Biogen News

      Loading Messages....

      {{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

      Loading Messages....
      No posts yet, be the first! No BIIB Message Board. Create One! See More Posts on BIIB Message Board See More Message Board Posts

      Historical BIIB Price Data
      Period Open High Low VWAP Avg. Daily Vol Change %
      1 Week190.72210.83189.44198.321,804,14417.789.32%
      1 Month215.69215.70189.44200.081,239,227-7.19-3.33%
      3 Months245.93246.48189.44215.981,280,939-37.43-15.22%
      6 Months248.41268.74189.44229.611,171,902-39.91-16.07%
      1 Year278.59319.76189.44253.161,104,373-70.09-25.16%
      3 Years264.45468.2499187.16265.971,232,179-55.95-21.16%
      5 Years230.25468.2499187.16269.561,382,134-21.75-9.45%

      Biogen Description

      Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.

      Your Recent History

      NASDAQ
      BIIB
      Biogen
      Delayed Upgrade Clock